1. Home
  2. KGS vs RYTM Comparison

KGS vs RYTM Comparison

Compare KGS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kodiak Gas Services Inc.

KGS

Kodiak Gas Services Inc.

HOLD

Current Price

$59.08

Market Cap

6.8B

Sector

N/A

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$102.10

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGS
RYTM
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
5.8B
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
KGS
RYTM
Price
$59.08
$102.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
14
Target Price
$57.17
$131.14
AVG Volume (30 Days)
1.6M
646.7K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
2.93%
N/A
EPS Growth
58.93
28.34
EPS
0.20
N/A
Revenue
$1,308,100,000.00
N/A
Revenue This Year
$12.30
$55.34
Revenue Next Year
$7.96
$86.06
P/E Ratio
$326.40
N/A
Revenue Growth
12.83
N/A
52 Week Low
$30.06
$74.50
52 Week High
$77.68
$122.20

Technical Indicators

Market Signals
Indicator
KGS
RYTM
Relative Strength Index (RSI) 33.36 46.08
Support Level $55.10 $98.30
Resistance Level $59.29 $113.51
Average True Range (ATR) 2.95 3.76
MACD -0.69 -1.65
Stochastic Oscillator 1.69 11.09

Price Performance

Historical Comparison
KGS
RYTM

About KGS Kodiak Gas Services Inc.

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: